Cargando…
Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers
Basal-like/triple-negative breast cancers (TNBCs) are among the most aggressive forms of breast cancer, and disproportionally affects young premenopausal women and women of African descent. Patients with TNBC suffer a poor prognosis due in part to a lack of molecularly targeted therapies, which repr...
Autores principales: | Song, W, Hwang, Y, Youngblood, V M, Cook, R S, Balko, J M, Chen, J, Brantley-Sieders, D M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629103/ https://www.ncbi.nlm.nih.gov/pubmed/28581527 http://dx.doi.org/10.1038/onc.2017.170 |
Ejemplares similares
-
Oncogenic Functions and Therapeutic Targeting of EphA2 in Cancer
por: Wilson, Kalin, et al.
Publicado: (2021) -
Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors
por: Hatano, Manabu, et al.
Publicado: (2004) -
EphA2 Is a Clinically Relevant Target for Breast Cancer Bone Metastatic Disease
por: Vaught, David B, et al.
Publicado: (2021) -
EphA5 and EphA6: regulation of neuronal and spine morphology
por: Das, Gitanjali, et al.
Publicado: (2016) -
Ephrin Receptors (Eph): EphA1, EphA5, and EphA7 Expression in Uveal Melanoma—Associations with Clinical Parameters and Patient Survival
por: Gajdzis, Malgorzata, et al.
Publicado: (2020)